DBV Technologies reported 1.53M in Sales Revenues for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Sales Change
DBV Technologies DBVT:US 1.53M 1.02M
Acadia Pharmaceuticals ACAD:US $ 134.56M 19.1M
Alnylam Pharmaceuticals ALNY:US $ 224.82M 11.56M
Amarin AMRN:US $ 94.44M 0.19M
Biocryst Pharmaceuticals BCRX:US $ 65.53M 15.61M
Biomarin Pharmaceutical BMRN:US $ 533.8M 14.44M
Eleven Biotherapeutics EBIO:US $ 0M 20M
Esperion Therapeutics ESPR:US $ 18.84M 5K
Halozyme Therapeutics HALO:US $ 152.36M 35.09M
Insmed INSM:US $ 65.22M 12.11M
Intercept Pharmaceuticals ICPT:US $ 71.76M 16.82M
IONIS PHARMACEUT IONS:US $ 133.79M 8.13M
Neurocrine Biosciences NBIX:US $ 378.2M 67.6M
Ptc Therapeutics PTCT:US $ 165.53M 16.79M
Sarepta Therapeutics SRPT:US $ 233.49M 22.66M
Ultragenyx Pharmaceutical RARE:US $ 89.34M 9.41M
United Therapeutics UTHR:US $ 466.9M 5M
YTE INCY:US $ 911.4M 178.16M